Patient P-01588

Synthetic patientNBL-101 · Day 118 · 25–34 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Stable

Discontinuation risk

50%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −26% vs expected — Dietary Support Protocol NP-02
Day 48 Tolerance state changed — Unstable → Improving
Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 57 GI-04 recommended — GI Support Protocol GI-04
Day 58 Patient accepted — Started GI-04 in the companion
Day 65 ME-01 recommended — Monitoring Escalation ME-01
Day 66 GI symptom burden −32% vs expected — GI Support Protocol GI-04
Day 66 Patient accepted — Started ME-01 in the companion
Day 69 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 72 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 50.

Primary contributors, last 14 days

GI instability-7
Inflammatory activity-5
Treatment adherence+5
Toxicity+2

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −26%
GI Support Protocol GI-04Day 57
Result: symptom burden −32%
Monitoring Escalation ME-01Day 65
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

73%

probability of meaningful tolerance improvement

284 similar trajectories
94% showed improvement
median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

30.9/100

improving · -4.2 vs previous 14 d

Toxicity

Blood

47.2/100

worsening · +4.8 vs previous 14 d

Sleep quality

Wearable

51.5/100

improving · +3.1 vs previous 14 d

Energy level

Daily log

4.6/10

improving · +0.4 vs previous 14 d

Stress level

Daily log

5.4/10

stable · +0.0 vs previous 14 d

Steps

Wearable

8,440

stable · -2 vs previous 14 d

Adherence

Companion

63 %

stable · +0.3 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 57 from the failing basin, 31 from restoration.

Good elements to keep

GI Support Protocol GI-04
intervention · steering +53.9
Dietary Support Protocol NP-02
intervention · steering +39.4
Monitoring Escalation ME-01
intervention · steering +4.9

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
FUT2 non-secretor
hidden · steering -10.6
Rapid metabolizer
hidden · steering -8
Low microbial diversity
hidden · steering -7.7
Spicy / capsaicin
detractor · GI +3.8 next day
Dietary fat load
detractor · GI +3.7 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Spicy / capsaicin
+3.8detractor · 95%
Dietary fat load
+3.7detractor · 95%
Insoluble fibre
+2.3detractor · 80%
Histamine load
+2.1detractor · 73%
Simple carbohydrates
+2.1detractor · 69%
Alcohol
+1no signal · 33%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓60
- MicrobiomeButyrate capacity 23/100
- MicrobiomeF. prausnitzii depleted
Inflammatory signalling ↓45
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
Drug metabolism and exposure ↑20
- BloodToxicity index 47

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.2 · butyrate capacity 23/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 52 ms
Sleep: 7.5 h
Steps: 8,168
Resting HR: 68 bpm

Daily log: GI score 31, nutritional resilience 54, adherence 63.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01714	50%	S14	GI-04	improved	66
P-01657	49%	S14	GI-04	improved	62
P-01678	49%	S14	GI-04	improved	44
P-01438	48%	S14	GI-04	improved	56
P-01617	47%	S14	SC-12	improved	50
P-01432	45%	S14	GI-04	improved	46
P-01566	45%	S09	GI-04	improved	52
P-01383	44%	S14	NP-02	improved	40
P-01323	43%	S14	GI-04	improved	50
P-01458	43%	S14	GI-04	improved	44
P-01627	42%	S14	GI-04	improved	54
P-01635	42%	S02	GI-04	improved	49